Jeri Hilleman

Jeryl L. Hilleman, also known as Jeri Hilleman, has been appointed as the Monitor by the Federal Trade Commission (FTC) to oversee Amgen's compliance with the consent agreement related to its acquisition of Horizon Therapeutics.23

Key points about Jeri Hilleman's role:

1. She was appointed to ensure Amgen adheres to the terms of the consent order finalized in December 2023.3

2. Her responsibilities include:

   • Reviewing Amgen's contracts with insurers within 30 days of signing4
   • Overseeing Amgen's compliance with the agreement prohibiting bundling practices4
   • Submitting reports to the FTC and participating states3

3. Her appointment is part of the settlement that allows Amgen's $27.8 billion acquisition of Horizon Therapeutics to proceed.14

4. The monitoring role will be in effect for 15 years, as stipulated in the consent order.3

5. Inquiries related to her role as Monitor can be directed to her email: altamira.jlh@gmail.com.2

While I don't have specific information about Jeri Hilleman's LinkedIn profile, her appointment as the FTC Monitor for this high-profile pharmaceutical acquisition underscores her expertise and credibility in overseeing complex corporate compliance matters.